Recruitment and retention of participants for an international type 1 diabetes prevention trial: a coordinators' perspective

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Recruitment and retention of participants for an international type 1 diabetes prevention trial : a coordinators' perspective. / Franciscus, Margaret; Nucci, Anita; Bradley, Brenda; Suomalainen, Heli; Greenberg, Ellen; Laforte, Diane; Kleemola, Paivi; Hyytinen, Mila; Salonen, Marja; Martin, Mary Jean; Catte, Daniel; Catteau, Jacki; TRIGR Investigators ; Mandrup-Poulsen, Thomas.

In: Clinical Trials, Vol. 11, No. 2, 04.2014, p. 150-8.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Franciscus, M, Nucci, A, Bradley, B, Suomalainen, H, Greenberg, E, Laforte, D, Kleemola, P, Hyytinen, M, Salonen, M, Martin, MJ, Catte, D, Catteau, J, TRIGR Investigators & Mandrup-Poulsen, T 2014, 'Recruitment and retention of participants for an international type 1 diabetes prevention trial: a coordinators' perspective', Clinical Trials, vol. 11, no. 2, pp. 150-8. https://doi.org/10.1177/1740774513510070

APA

Franciscus, M., Nucci, A., Bradley, B., Suomalainen, H., Greenberg, E., Laforte, D., Kleemola, P., Hyytinen, M., Salonen, M., Martin, M. J., Catte, D., Catteau, J., TRIGR Investigators, & Mandrup-Poulsen, T. (2014). Recruitment and retention of participants for an international type 1 diabetes prevention trial: a coordinators' perspective. Clinical Trials, 11(2), 150-8. https://doi.org/10.1177/1740774513510070

Vancouver

Franciscus M, Nucci A, Bradley B, Suomalainen H, Greenberg E, Laforte D et al. Recruitment and retention of participants for an international type 1 diabetes prevention trial: a coordinators' perspective. Clinical Trials. 2014 Apr;11(2):150-8. https://doi.org/10.1177/1740774513510070

Author

Franciscus, Margaret ; Nucci, Anita ; Bradley, Brenda ; Suomalainen, Heli ; Greenberg, Ellen ; Laforte, Diane ; Kleemola, Paivi ; Hyytinen, Mila ; Salonen, Marja ; Martin, Mary Jean ; Catte, Daniel ; Catteau, Jacki ; TRIGR Investigators ; Mandrup-Poulsen, Thomas. / Recruitment and retention of participants for an international type 1 diabetes prevention trial : a coordinators' perspective. In: Clinical Trials. 2014 ; Vol. 11, No. 2. pp. 150-8.

Bibtex

@article{15beda48c9244a548fa2b427980fad13,
title = "Recruitment and retention of participants for an international type 1 diabetes prevention trial: a coordinators' perspective",
abstract = "BACKGROUND: The Trial to Reduce Insulin Dependent Diabetes Mellitus in the Genetically at Risk (TRIGR) is the first multicenter international type 1 diabetes (T1D) prevention trial to be undertaken. A unique feature of TRIGR has been recruitment of eligible pregnant women and enrollment of newborns for long-term follow-up assessments.PURPOSE: Our purpose is to summarize the recruitment and retention strategies used to conduct TRIGR from the perspective of the study coordinators.METHODS: TRIGR was designed to test whether weaning to formula containing hydrolyzed versus intact cow's milk protein would be efficacious in decreasing risk for development of T1D-associated autoantibodies and T1D among infants identified to be at increased risk for T1D based on their human leukocyte antigen (HLA) profile and family history. Multiple strategies tailored to local issues were required to enroll and follow the target number of infants.RESULTS: This study was conducted in the United States, Canada, Australia, and 12 countries in Europe. Of the 5606 mothers registered worldwide, 5000 of their infants were randomized. Of these, 2159 were HLA eligible and enrolled in the 8-month intervention and 10-year follow-up phases of this study. The TRIGR study met the accrual goal after 4.7 years of recruitment, 2.7 years longer than projected initially. Challenges included difficulty in finding fathers with T1D, a higher than expected rate of premature delivery among T1D mothers, and implementation of new privacy regulations mid-trial. The majority of participants were recruited from primary care antenatal clinics located near the study centers and from a general hospital or pediatric center that was affiliated with a TRIGR Study center. Internet and magazine advertisements were found to be useful for recruitment of families. Alternative follow-up strategies are offered to families who wish to reduce or discontinue participation.LIMITATIONS: Our experience is limited to a single international multicenter trial.CONCLUSIONS: TRIGR coordinators played key roles in the recruitment and intervention periods and continue to be instrumental in retaining families and children during the 10-year follow-up period for each child.",
author = "Margaret Franciscus and Anita Nucci and Brenda Bradley and Heli Suomalainen and Ellen Greenberg and Diane Laforte and Paivi Kleemola and Mila Hyytinen and Marja Salonen and Martin, {Mary Jean} and Daniel Catte and Jacki Catteau and {TRIGR Investigators} and Thomas Mandrup-Poulsen",
year = "2014",
month = apr,
doi = "10.1177/1740774513510070",
language = "English",
volume = "11",
pages = "150--8",
journal = "Clinical Trials",
issn = "1740-7745",
publisher = "SAGE Publications",
number = "2",

}

RIS

TY - JOUR

T1 - Recruitment and retention of participants for an international type 1 diabetes prevention trial

T2 - a coordinators' perspective

AU - Franciscus, Margaret

AU - Nucci, Anita

AU - Bradley, Brenda

AU - Suomalainen, Heli

AU - Greenberg, Ellen

AU - Laforte, Diane

AU - Kleemola, Paivi

AU - Hyytinen, Mila

AU - Salonen, Marja

AU - Martin, Mary Jean

AU - Catte, Daniel

AU - Catteau, Jacki

AU - TRIGR Investigators

AU - Mandrup-Poulsen, Thomas

PY - 2014/4

Y1 - 2014/4

N2 - BACKGROUND: The Trial to Reduce Insulin Dependent Diabetes Mellitus in the Genetically at Risk (TRIGR) is the first multicenter international type 1 diabetes (T1D) prevention trial to be undertaken. A unique feature of TRIGR has been recruitment of eligible pregnant women and enrollment of newborns for long-term follow-up assessments.PURPOSE: Our purpose is to summarize the recruitment and retention strategies used to conduct TRIGR from the perspective of the study coordinators.METHODS: TRIGR was designed to test whether weaning to formula containing hydrolyzed versus intact cow's milk protein would be efficacious in decreasing risk for development of T1D-associated autoantibodies and T1D among infants identified to be at increased risk for T1D based on their human leukocyte antigen (HLA) profile and family history. Multiple strategies tailored to local issues were required to enroll and follow the target number of infants.RESULTS: This study was conducted in the United States, Canada, Australia, and 12 countries in Europe. Of the 5606 mothers registered worldwide, 5000 of their infants were randomized. Of these, 2159 were HLA eligible and enrolled in the 8-month intervention and 10-year follow-up phases of this study. The TRIGR study met the accrual goal after 4.7 years of recruitment, 2.7 years longer than projected initially. Challenges included difficulty in finding fathers with T1D, a higher than expected rate of premature delivery among T1D mothers, and implementation of new privacy regulations mid-trial. The majority of participants were recruited from primary care antenatal clinics located near the study centers and from a general hospital or pediatric center that was affiliated with a TRIGR Study center. Internet and magazine advertisements were found to be useful for recruitment of families. Alternative follow-up strategies are offered to families who wish to reduce or discontinue participation.LIMITATIONS: Our experience is limited to a single international multicenter trial.CONCLUSIONS: TRIGR coordinators played key roles in the recruitment and intervention periods and continue to be instrumental in retaining families and children during the 10-year follow-up period for each child.

AB - BACKGROUND: The Trial to Reduce Insulin Dependent Diabetes Mellitus in the Genetically at Risk (TRIGR) is the first multicenter international type 1 diabetes (T1D) prevention trial to be undertaken. A unique feature of TRIGR has been recruitment of eligible pregnant women and enrollment of newborns for long-term follow-up assessments.PURPOSE: Our purpose is to summarize the recruitment and retention strategies used to conduct TRIGR from the perspective of the study coordinators.METHODS: TRIGR was designed to test whether weaning to formula containing hydrolyzed versus intact cow's milk protein would be efficacious in decreasing risk for development of T1D-associated autoantibodies and T1D among infants identified to be at increased risk for T1D based on their human leukocyte antigen (HLA) profile and family history. Multiple strategies tailored to local issues were required to enroll and follow the target number of infants.RESULTS: This study was conducted in the United States, Canada, Australia, and 12 countries in Europe. Of the 5606 mothers registered worldwide, 5000 of their infants were randomized. Of these, 2159 were HLA eligible and enrolled in the 8-month intervention and 10-year follow-up phases of this study. The TRIGR study met the accrual goal after 4.7 years of recruitment, 2.7 years longer than projected initially. Challenges included difficulty in finding fathers with T1D, a higher than expected rate of premature delivery among T1D mothers, and implementation of new privacy regulations mid-trial. The majority of participants were recruited from primary care antenatal clinics located near the study centers and from a general hospital or pediatric center that was affiliated with a TRIGR Study center. Internet and magazine advertisements were found to be useful for recruitment of families. Alternative follow-up strategies are offered to families who wish to reduce or discontinue participation.LIMITATIONS: Our experience is limited to a single international multicenter trial.CONCLUSIONS: TRIGR coordinators played key roles in the recruitment and intervention periods and continue to be instrumental in retaining families and children during the 10-year follow-up period for each child.

U2 - 10.1177/1740774513510070

DO - 10.1177/1740774513510070

M3 - Journal article

C2 - 24216218

VL - 11

SP - 150

EP - 158

JO - Clinical Trials

JF - Clinical Trials

SN - 1740-7745

IS - 2

ER -

ID: 113810345